Empaveli
Payments companies reported to CMS as associated with Empaveli. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Empaveli, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Empaveli
These are the largest totals companies reported as associated with Empaveli. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jorge Leguizamo | Lawrenceville, GA | Hematology & Oncology | $72,199.06 |
| Caroline Piatek | Los Angeles, CA | Hematology (Internal Medicine) | $71,817.22 |
| Brian Mulherin | Indianapolis, IN | Hematology & Oncology | $62,949.38 |
| Prince Anand | Danville, PA | Nephrology (Internal Medicine) | $58,853.74 |
| Jamie Koprivnikar | Hackensack, NJ | Medical Oncology | $49,185.47 |
| Bart Scott | Seattle, WA | Medical Oncology | $36,058.85 |
| Chelsea Crilly | Austin, TX | Family | $31,333.40 |
| Tariq Shah | Los Angeles, CA | Nephrology (Internal Medicine) | $30,685.03 |
| Sonata Jodele | Cincinnati, OH | Pediatric Hematology-Oncology | $29,925.00 |
| Stefanie Benoit | Cincinnati, OH | Pediatric Nephrology | $28,277.61 |
Prescribed Empaveli?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.